{"id":453487,"date":"2021-03-09T07:33:12","date_gmt":"2021-03-09T12:33:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453487"},"modified":"2021-03-09T07:33:12","modified_gmt":"2021-03-09T12:33:12","slug":"nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/","title":{"rendered":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, March  09, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RjuLQLM8T8rTgL8ZjR7L48cY2dljH8VvGrAATo3r9LwMd-O4Sn75JypOhvqropDS4dCEqHd-BbvUaFmN8oeWFYybG648jMJFllAeK63jSqM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Nurix Therapeutics, Inc.<\/a>\u00a0(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today\u00a0announced\u00a0that Arthur Sands, M.D., Ph.D., Nurix\u2019s chief executive officer, will participate and present at the following conferences in March:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Guggenheim Targeted Protein Degradation Day Virtual Conference<\/strong><br \/>\n          <br \/>Tuesday, March 16, 2021 10:30 &#8211; 11:30 AM EDT <br \/>Panel discussion: <em>Targeted Protein Degradation \u2013 Different Approaches, Same Goal?<\/em><\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Oppenheimer 31<\/strong><br \/>\n          <sup><br \/>\n            <strong>st<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Conference (Virtual)<\/strong><br \/>\n          <br \/>Wednesday, March 17<sup>th<\/sup> at 3:10 &#8211; 3:40 PM EDT<br \/>Nurix Corporate Presentation<\/li>\n<\/ul>\n<p>The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kG-G5Gzx1Aq2ifJSsWq3cN3aqJZlKM1BUb-zxEIoR6IMhR7Omv15ByT4E4ip6IfenwZcAGUMNXnAWb_3q8vgvOFmvY179teaE6WWifu45R9GQDLj7NMHymDW1P3-6kn5vqQemNdoB9WCXg0IOgfvtg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Events and Presentations<\/a>. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.<\/p>\n<p>\n        <strong>About Nurix Therapeutics, Inc. <\/strong><br \/>\n        <br \/>Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix\u2019s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix\u2019s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix\u2019s wholly owned pipeline includes targeted protein degraders of Bruton\u2019s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iflSuBlZh3KOcCdegVzjckD1k9qLAGkd9yPqxVy-nY_de05Sy_xH2LubQ0dNWDozNf8Lyr7qllXouQ8_6zifBw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.nurix.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Investors:<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Media:<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Jason Kantor, Ph.D.<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Elizabeth Wolffe, Ph.D.<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Nurix Therapeutics, Inc.<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Wheelhouse Life Science Advisors<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <a href=\"mailto:jkantor@nurixtx.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>jkantor@nurixtx.com<\/u><br \/>\n            <\/a>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <u><br \/>\n              <a href=\"mailto:lwolffe@wheelhouselsa.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lwolffe@wheelhouselsa.com<\/a><br \/>\n            <\/u>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/227fe29a-410c-44b4-91df-c9525a5e4861\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc.\u00a0(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today\u00a0announced\u00a0that Arthur Sands, M.D., Ph.D., Nurix\u2019s chief executive officer, will participate and present at the following conferences in March: Guggenheim Targeted Protein Degradation Day Virtual Conference Tuesday, March 16, 2021 10:30 &#8211; 11:30 AM EDT Panel discussion: Targeted Protein Degradation \u2013 Different Approaches, Same Goal? Oppenheimer 31 st Annual Healthcare Conference (Virtual) Wednesday, March 17th at 3:10 &#8211; 3:40 PM EDTNurix Corporate Presentation The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453487","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc.\u00a0(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today\u00a0announced\u00a0that Arthur Sands, M.D., Ph.D., Nurix\u2019s chief executive officer, will participate and present at the following conferences in March: Guggenheim Targeted Protein Degradation Day Virtual Conference Tuesday, March 16, 2021 10:30 &#8211; 11:30 AM EDT Panel discussion: Targeted Protein Degradation \u2013 Different Approaches, Same Goal? Oppenheimer 31 st Annual Healthcare Conference (Virtual) Wednesday, March 17th at 3:10 &#8211; 3:40 PM EDTNurix Corporate Presentation The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on &hellip; Continue reading &quot;Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T12:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences\",\"datePublished\":\"2021-03-09T12:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/\",\"name\":\"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\",\"datePublished\":\"2021-03-09T12:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc.\u00a0(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today\u00a0announced\u00a0that Arthur Sands, M.D., Ph.D., Nurix\u2019s chief executive officer, will participate and present at the following conferences in March: Guggenheim Targeted Protein Degradation Day Virtual Conference Tuesday, March 16, 2021 10:30 &#8211; 11:30 AM EDT Panel discussion: Targeted Protein Degradation \u2013 Different Approaches, Same Goal? Oppenheimer 31 st Annual Healthcare Conference (Virtual) Wednesday, March 17th at 3:10 &#8211; 3:40 PM EDTNurix Corporate Presentation The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on &hellip; Continue reading \"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T12:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences","datePublished":"2021-03-09T12:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/","name":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=","datePublished":"2021-03-09T12:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjY1NyM0MDU0Mjk4IzIyMDA2Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453487"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453487\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}